{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:05:59Z","timestamp":1792710359170,"version":"4.5.0"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.2169\/internalmedicine.5938-25","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T22:09:05Z","timestamp":1753913345000},"page":"732-736","source":"Crossref","is-referenced-by-count":2,"title":["Adult T-cell Leukemia Following Satralizumab Treatment for Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.2169","volume":"65","author":[{"given":"Kenzo","family":"Sakurai","sequence":"first","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Ashikawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Imaoka","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St. Marianna University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Sano","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St. Marianna University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, St. Marianna University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Yagishita","sequence":"additional","affiliation":[{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Araya","sequence":"additional","affiliation":[{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Horibe","sequence":"additional","affiliation":[{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Yamano","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine, Japan"},{"name":"Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol 93: 1053-1068, 2023.","DOI":"10.1002\/ana.26626"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Cree BAC, Bennett JL, Kim HJ, et al.; the N-MOmentum study investigators. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomized placebo-controlled phase 2\/3 trial. Lancet 394: 1352-1363, 2019.","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomized, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19: 402-412, 2020.","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381: 614-625, 2019.","DOI":"10.1056\/NEJMoa1900866"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomized, double-blind, placebo-controlled trial. Lancet Neurol 19: 298-306, 2020.","DOI":"10.1016\/S1474-4422(20)30066-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Meher BR, Mohanty RR, Dash A. Review of satralizumab for neuromyelitis optica spectrum disorder: a new biologic agent targeting the interleukin-6 receptor. Cureus 16: e55100, 2024.","DOI":"10.7759\/cureus.55100"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Smolen JS, Beaulieu A, Rubbert-Roth A, et al.; the OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 371: 987-997, 2008.","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset Still&apos;s disease refractory to glucocorticoid treatment: a randomized, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77: 1720-1729, 2018.","DOI":"10.1136\/annrheumdis-2018-213920"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ko PH, Kuo MH, Kao IT, Wu CY, Tseng CW, Shao SC. The risk of hepatitis B virus reactivation in rheumatoid arthritis patients receiving tocilizumab: a systematic review and meta-analysis. Viruses 16: 78, 2024.","DOI":"10.3390\/v16010078"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Mourgues C, Henquell C, Tatar Z, et al. Monitoring of Epstein-Barr virus (EBV)\/cytomegalovirus (CMV)\/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. Joint Bone Spine 83: 412-415, 2016.","DOI":"10.1016\/j.jbspin.2015.07.009"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type-C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77: 7415-7419, 1980.","DOI":"10.1073\/pnas.77.12.7415"},{"key":"12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(86)91298-5","volume":"1","author":"M Osame","year":"1986","unstructured":"12. Osame M, Usuku K, Izumo S. HTLV-1 associated myelopathy, a new clinical entity. Lancet 1: 1031-1032, 1986.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cassar O, Gessain A. Serological and molecular methods to study the epidemiological aspects of human T-cell lymphotropic virus type I infection. Methods Mol Biol 1582: 3-24, 2017.","DOI":"10.1007\/978-1-4939-6872-5_1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol 79: 428-437, 1991.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakamura H, Ueki Y, Sato S, et al. Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. Intern Med 52: 1983-1986, 2013.","DOI":"10.2169\/internalmedicine.52.0468"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Terada Y, Kamoi K, Ohno-Matsui K, et al. Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated conditions: a case report. Medicine (Baltimore) 96: e6021, 2017.","DOI":"10.1097\/MD.0000000000006021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Higuchi Y, Yanaga J, Mitagami Y, et al. HTLV-1 induces T-cell malignancy and inflammation by viral antisense factor-mediated modulation of the cytokine signaling. Proc Natl Acad Sci U S A 117: 13740-13749, 2020.","DOI":"10.1073\/pnas.1922884117"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Iwao C, Umekita K, Miyauchi S, et al. Effective treatment with tocilizumab in a rheumatoid arthritis patient complicated with human T-cell leukemia virus type 1-associated myelopathy. Intern Med 59: 1891-1897, 2020.","DOI":"10.2169\/internalmedicine.4455-20"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Endo Y, Fukui S, Umekita K, et al. Effectiveness and safety of nontumor necrosis factor inhibitor therapy for antihuman T-cell leukemia virus type 1 antibody-positive rheumatoid arthritis. Mod Rheumatol 31: 972-978, 2021.","DOI":"10.1080\/14397595.2020.1847802"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Iwanaga M, Watanabe T, Utsunomiya A, et al.; the Joint Study on Predisposing Factors of ATL Development investigators. Human T-cell leukemia virus type 1 (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116: 1211-1219, 2010.","DOI":"10.1182\/blood-2009-12-257410"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Firouzi S, Farmanbar A, Nakai K, et al. Clonality of HTLV-1-infected T cells as a risk indicator for the development and progression of adult T-cell leukemia. Blood Adv 1: 1955-1965, 2017.","DOI":"10.1182\/bloodadvances.2017005900"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Wada Y, Sato T, Hasegawa H, et al. RAISING is a high-performance method for identifying random transgene integration sites. Commun Biol 5: 535, 2022.","DOI":"10.1038\/s42003-022-03467-w"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Gillet NA, Malani N, Melamed A, et al. The host genomic environment determines the abundance of HTLV-1-infected T-cell clones. Blood 117: 3113-3122, 2011.","DOI":"10.1182\/blood-2010-10-312926"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nagasaka M, Yamagishi M, Yagishita N, et al. Mortality and risk of progression to adult T-cell leukemia\/lymphoma in HTLV-1-associated myelopathy\/tropical spastic paraparesis. Proc Natl Acad Sci U S A 117: 11685-11691, 2020.","DOI":"10.1073\/pnas.1920346117"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Rowan AG, Dillon R, Witkover A, et al. Evolution of retrovirus-infected premalignant T-cell clones before adult T-cell leukemia\/lymphoma diagnosis. Blood 135: 2023-2032, 2020.","DOI":"10.1182\/blood.2019002665"},{"key":"26","unstructured":"26. Nagao T, Takahashi N, Saitoh H, et al. Adult T-cell leukemia-lymphoma developed from an HTLV-1 carrier during treatment of B-cell lymphoma-associated hemophagocytic syndrome. Rinsho Ketsueki (Jpn J Clin Hematol) 53: 2008-2012, 2012."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5938-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:46:04Z","timestamp":1772855164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/5\/65_5938-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5938-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"5938-25"}}